Lack of evolutionary convergence in multiple primary lung cancer suggests insufficient specificity of personalized therapy

Cheng, Hua; Guo, Ziyan; Zhang, Xiaoyu; Wang, Xiaojin; Li, Zizhang; Huo, Wenwen; Zhong, Hongcheng; Li, Xiaojian; Wu, Xia; Li, Wenhao; Chen, Zhuo-Wen; Wu, Tian-Chi; Gan, Xiangfeng; Zhong, Beilong; Lyubetsky, Vassily; Rusin, L.Y.; Yang, Jun; Zhao, Qiyi; Cao, Qingdong; Yang, Jinfu

doi:10.1016/j.jgg.2022.11.005

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the limited sample sizes, they present promising new insights for personalized therapy by targeting the convergent pathway. However, a recent study that included 101 samples showed no evidence of convergence in the different lesions 131 . But it is noteworthy that when the mutation used for analysis was restrained within the cancer driver genes/pathways, the levels of convergence increased, though still not statistically differed.…”

Section: Etiology Evolutionary Trajectory Of Mplc and Clinical Implic...mentioning

confidence: 92%

“…However, a recent study that included 101 samples showed no evidence of convergence in the different lesions. 131 But it is noteworthy that when the mutation used for analysis was restrained within the cancer driver genes/pathways, the levels of convergence increased, though still not statistically differed. These suggest that certain MPLCs may have lesions with convergent mutations/pathways that could be potential candidates for targeted therapy.…”

Section: Evolutionary Trajectorymentioning

confidence: 99%

See 1 more Smart Citation

Multiple primary lung cancer: Updates and perspectives

Wang,

Zhang,

Wang

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Management of multiple primary lung cancer (MPLC) remains challenging, partly due to its increasing incidence, especially with the significant rise in cases of multiple lung nodules caused by low‐dose computed tomography screening. Moreover, the indefinite pathogenesis, diagnostic criteria, and treatment selection add to the complexity. In recent years, there have been continuous efforts to dissect the molecular characteristics of MPLC and explore new diagnostic approaches as well as treatment modalities, which will be reviewed here, with a focus on newly emerging evidence and future perspectives, hope to provide new insights into the management of MPLC and serve as inspiration for future research related to MPLC.

show abstract

Section: Etiology Evolutionary Trajectory Of Mplc and Clinical Implic...mentioning

confidence: 92%

Section: Evolutionary Trajectorymentioning

confidence: 99%

Multiple primary lung cancer: Updates and perspectives

Wang,

Zhang,

Wang

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Transferring a new Fusarium head blight resistance locus FhbRc1 from Roegneria ciliaris into wheat by developing alien translocation lines

et al. 2023

View full text Add to dashboard Cite

Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer

Wang,

Huang,

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

The increase in the detection rate of synchronous multiple primary lung cancer (MPLC) has posed remarkable clinical challenges due to the limited understanding of its pathogenesis and molecular features. Here, comprehensive comparisons of genomic and immunologic features between MPLC and solitary lung cancer nodule (SN), as well as different lesions of the same patient, were performed. Compared with SN, MPLC displayed a lower rate of EGFR mutation but higher rates of BRAF, MAP2K1, and MTOR mutation, which function exactly in the upstream and downstream of the same signaling pathway. Considerable heterogeneity in T cell receptor (TCR) repertoire exists among not only different patients but also among different lesions of the same patient. Invasive lesions of MPLC exhibited significantly higher TCR diversity and lower TCR expansion than those of SN. Intriguingly, different lesions of the same patient always shared a certain proportion of TCR clonotypes. Significant clonal expansion could be observed in shared TCR clonotypes, particularly in those existing in all lesions of the same patient. In conclusion, this study provided evidences of the distinctive mutational landscape, activation of oncogenic signaling pathways, and TCR repertoire in MPLC as compared with SN. The significant clonal expansion of shared TCR clonotypes demonstrated the existence of immune commonality among different lesions of the same patient and shed new light on the individually tailored precision therapy for MPLC.

show abstract

Lack of evolutionary convergence in multiple primary lung cancer suggests insufficient specificity of personalized therapy

Cited by 4 publications

References 41 publications

Multiple primary lung cancer: Updates and perspectives

Multiple primary lung cancer: Updates and perspectives

Transferring a new Fusarium head blight resistance locus FhbRc1 from Roegneria ciliaris into wheat by developing alien translocation lines

Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer

Contact Info

Product

Resources

About